Kirk A. Staschke
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
263
Citations
3,263
Est. group size
~2
Recurring co-author estimate
Active years
33
Publishing since 1994
Kirk A. Staschke studies how cells sense and respond to stress, particularly nutrient and amino acid shortages, through protein kinases such as GCN2 and PERK that regulate the 'integrated stress response' and protein synthesis. Much of this work explores how cancer cells (including prostate cancer) exploit these stress-response pathways to survive, and how targeting them with drugs, dietary interventions like fasting, or combination therapies might improve treatment.
Publication activity grew sharply from a few papers per year before 2022 to a peak in 2023-2024, though this count is inflated by many supplementary-file entries counted as separate items.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~16 · 3% small-team papers (≤3 authors) · across 18 venues
- PERK protein kinase facilitates keratinocyte collective cell migration by engagement with cell adhesion molecules, independent of its kinase activity
Molecular Biology of the Cell · 2025
- Abstract 1515: GCN2 eIF2 kinase promotes polyamine metabolism and progression of prostate cancer
Cancer Research · 2025
- Abstract 7032: The role of general control nonderepressible 2 (GCN2) kinase in leukemogenesis and therapeutic response to L-asparaginase
Cancer Research · 2025
- Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer
Science Signaling · 2024
- Abstract 1691 Differential Response of GCN2 eIF2 Kinase to Specific Amino Acid Limitations in Prostate Cancer
Journal of Biological Chemistry · 2024
- Abstract 388: Identifying synthetic lethalities in GCN2 KO tumors using an <i>in vivo</i> targeted CRISPRi screen
Cancer Research · 2024
- A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells
Clinical Cancer Research · 2023
- PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
Clinical Cancer Research · 2023
- Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer models
Cancer Research · 2023
- Activation of GCN2 By HC-7366 Results in Significant Anti-Tumor Efficacy As Monotherapy and Overcomes Resistance Mechanisms When Combined with Venetoclax in AML
Blood · 2023
- Data from mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress
2023
- Supplementary Figure 1 from mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress
2023
- Supplementary Figure 1 from mTORC2 Balances AKT Activation and eIF2α Serine 51 Phosphorylation to Promote Survival under Stress
2023
- Abstract A30: Activation of GCN2 by HC-7366 results in significant anti-tumor efficacy as monotherapy and in combination with Venetoclax in AML models
Blood Cancer Discovery · 2023
- Data from PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
2023
- Cancer Research×17
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Journal of Biological Chemistry×3
- Clinical Cancer Research×2
- The FASEB Journal×2
- Ricardo A. Cordova
Biochemistry, Genetics and Molecular Biology · Indiana University
- Peter F. Ehrlich
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Mariana M. Cajaiba
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Gregory R. Dressler
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Peter C. Hollenhorst
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile